Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition

International Journal of Cancer

Volumn 121, Issue 6, 2007, Pages 1331-1338

  Travis, Ruth C ^a   Key, Timothy J ^a   Allen, Naomi E ^a   Appleby, Paul N ^a   Roddam, Andrew W ^a   Rinaldi, Sabina ^b   Egevad, Lars ^b   Gann, Peter H ^c   Rohrmann, Sabine ^d   Linseisen, Jakob ^d   Pischon, Tobias ^e   Boeing, Heiner ^e   Johnsen, Nina Føns ^f   Tjønneland, Anne ^f   Overvad, Kim ^g   Kiemeney, Lambertus ^h   Bueno De Mesquita, H Bas ⁱ   Bingham, Sheila ^j,k,l   Khaw, Kay Tee ^l   Tumino, Rosario ^m   Sieri, Sabina ⁿ   Vineis, Paolo ^o   Palli, Domenico ^p   Quirós, José Ramón ^q   Ardanaz, Eva ^r   Chirlaque, Maria Dolores ^s   Larrañaga, Nerea ^t   Gonzalez, Carlos ^u   Sanchez, Maria José ^v   Trichopoulou, Antonia ^w   Bikou, Chrysa ^w   Trichopoulos, Dimitrios ^x   Stattin, Pär ^y   Jenab, Mazda ^b   Ferrari, Pietro ^b   Slimani, Nadia ^b   Riboli, Elio ^o   Kaaks, Rudolf ^d   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^f INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^m CIVILE M P AREZZO HOSPITAL   (Italy)

ⁿ NATIONAL CANCER INSTITUTE   (Italy)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

^p CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^q Public Health and Health Planning Directorate   (Spain)

^r INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^s DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^t DEPARTMENT OF HEALTH   (Spain)

^u CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^v Escuela Andaluza de Salud Pblica   (Spain)

^w UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^x HELLENIC HEALTH FOUNDATION   (Greece)

^y UMEÅ UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Androgen; EPIC; Prospective; Prostate cancer; Serum

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTENEDIONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL;

AGE FACTORS; AGED; ANDROGENS; CASE-CONTROL STUDIES; COHORT STUDIES; EUROPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATIC NEOPLASMS; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN;

EID: 34548083070     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22814     Document Type: Article

References (46)

1. Ferlay J, Bray F, Pisani P, Parkin DM, eds. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 Version 2.0. Lyon: IARC Press, 2004.
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388-413.
3. Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000;3:157-72.
4. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004;92:237-53.
5. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-33.
6. Rosenberg AG, von Eschenbach AC. Hormonal therapy for prostate cancer. Semin Surg Oncol 1990;6:71-6.
7. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002:CD003506.
8. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
9. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999;80:930-4.
10. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE. 5-α-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-9.
11. Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001;57:930-5.
12. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262-9.
13. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
14. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410-16.
15. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
16. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
17. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-24.
18. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, Haynes RB, Henderson BE, Kaaks R, Stram DO, Thomas G, Thun MJ, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5:977-85.
19. Tukey JW. Exploratory data analysis. Reading, MA: Addison-Wesley, 1977. 44-9.
20. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
21. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Riboli E, Toniolo P, Kaaks R. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol B iomarkers Prev 2002;11:1065-71.
22. Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, McShane LM, Barrett MJ, Tangrea J, Taylor PR. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 1998;7:1069-74.
23. Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanen A, Knekt P. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999;86:312-15.
24. Stata Statistical Software: Release 9 [program]. College Station, TX: StataCorp LP, 2005.
25. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
26. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K, Mori M, Sakauchi F, Washio M, Ito Y, Suzuki K, Wakai K et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 2004;95:65-71.
27. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14:2257-60.
28. Brawley OW, Ford LG, Thompson l, Perlman JA, Kramer BS. 5-α-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 1994;3:177-82.
29. Horton R, Hawks D, Lobo R. 3α, 17β-androstanediol glucuronide in plasma. A marker of androgen action in idiopathic hirsutism. J Clin Invest 1982;69:1203-6.
30. Rittmaster RS, Thompson DL, Listwak S, Loriaux DL. Androstanediol glucuronide isomers in normal men and women and in men infused with labeled dihydrotestosterone. J Clin Endocrinol Metab 1988;66:212-16.
31. Rao PN, Burdett JE, Jr, Moore PH, Jr, Horton R. Isolation and identification of androstanediol glucuronide from human plasma. J Steroid Biochem 1987;28:565-9.
32. Thompson DL, Rittmaster RS, Rodriguez AM, Moore PH, Jr, Rao PN. Synthesis of new steroid haptens for radioimmunoassay. VIII. Development and validation of a specific radioimmunoassay for serum 5 α-androstane-3 α, 17 β-diol 17-glucuronide. J Steroid Biochem 1990;36:345-9.
33. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology 2002;59:251-5.
34. Paez A, Lujan M, Llanes L, Romero I, de la Cal MA, Miravalles E, Berenguer A. PSA-use in a Spanish industrial area. Eur Urol 2002;41:162-6.
35. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH, de Koning HJ. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003;105:394-9.
36. D'Ambrosio G, Samani F, Cancian M, De Mola C. Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. Eur J Cancer Prev 2004;13:383-6.
37. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004;94:51-6.
38. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2:27-32.
39. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27:25-31.
40. Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:621-5.
41. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev 2001;23:42-58.
42. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803.
43. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005;95:1146-52.
44. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 1992;74:939-42.
45. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002;11:1041-7.
46. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998;148:775-85.